ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO662

Patient and Physician Preferences for Treatments of Anemia in CKD: Insights From the Qualitative Pilot of a Choice Experiment

Session Information

  • Anemia and Iron Metabolism
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Richards, Anna, GlaxoSmithKline, Brentford, Middlesex, United Kingdom
  • Seo, Jaein, Evidera, Bethesda, Maryland, United States
  • Mulnick, Sarah, Evidera, Bethesda, Maryland, United States
  • Lu, Ember, GlaxoSmithKline, Collegeville, Pennsylvania, United States
  • Okoro, Tony, GlaxoSmithKline, Collegeville, Pennsylvania, United States
  • Heidenreich, Sebastian, Evidera, London, United Kingdom
  • Refoios Camejo, Rodrigo, GlaxoSmithKline, Brentford, Middlesex, United Kingdom
Background

A choice experiment (CE) was developed following literature review and qualitative interviews to understand patient/physician preferences for treatments of anemia of CKD. This pilot phase asked CE participants to make trade-offs between five treatment attributes.

Methods

The CE was pilot tested in virtual interviews with non-dialysis (ND; CKD stages 3–5) and peritoneal dialysis (PD) patients and nephrologists in US, Germany and Japan. Interviews explored if CE was understandable; the attributes relevant; and participants willing and able to make trade-offs. A think-aloud method from cognitive psychology was used to observe participants’ understanding of the CE. Interviewers completed structured notes templates with their observations. Participants were asked if attributes of treatment profiles were more and less important to them when making choices.

Results

18 patients (ND=13; PD=5) and 12 nephrologists participated. Attributes and levels were considered relevant and meaningful; relative importance within treatment profiles differed (Table). Patients focused more on route and frequency of administration (n=11, 61%) and reducing fatigue (n=10, 56%); physicians prioritized keeping Hb levels within target range (n=9, 75%) and 1-year risk of major cardiovascular events (n=6, 50%). Dosing restriction requirement (required time interval between taking phosphorous or iron supplements and anemia of CKD treatment) was less important for some patients and physicians (n=5, 28%; n=4, 33%), but more important to other patients (n=4, 22%).

Conclusion

Pilot testing met objectives for attribute comprehension, relevance, and tradability. Differences in importance of attributes presented in treatment profiles suggest divergent treatment priorities and presence of preference heterogeneity.